Y-27632 Dihydrochloride: Selective ROCK Inhibitor for Cytoskeletal Research

Executive Summary: Y-27632 dihydrochloride is a cell-permeable, small-molecule inhibitor that selectively targets ROCK1 and ROCK2, exhibiting IC₅₀ values of approximately 140 nM and a K_i of 300 nM, respectively [APExBIO]. It displays over 200-fold selectivity versus related kinases such as PKC, PKA, MLCK, and PAK [Y-27632.com]. By disrupting Rho-mediated formation of actin stress fibers, it modulates cell cycle progression and cytokinesis [Zhang et al., 2025]. Y-27632 is highly soluble in DMSO, ethanol, and water under specified conditions, and is widely used to support stem cell viability, suppress tumor invasion, and enhance reproducibility in cell biology workflows [Surface-Antigen-208-215-Hepatitis-B-Virus.com]. APExBIO offers the A3008 kit as a reference standard for specificity and performance.

Biological Rationale

The Rho/ROCK signaling pathway orchestrates cytoskeletal dynamics, cell motility, proliferation, and survival. ROCK1 and ROCK2 are serine/threonine kinases activated downstream of RhoA GTPase. Their activity regulates the assembly of actin stress fibers and focal adhesions. In mammalian cells, ROCK-driven cytoskeletal rearrangement controls cell shape, migration, and division. Aberrant Rho/ROCK signaling is implicated in cancer progression, metastasis, and fibrosis. In the small intestine, stem cell compartments rely on cytoskeletal homeostasis for regeneration and barrier function [Zhang et al., 2025]. Targeted inhibition of ROCK kinases is therefore a strategy to dissect cytoskeletal regulation, enhance stem cell survival, and modulate tumor invasion.

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride binds to the ATP-binding pocket of ROCK1 and ROCK2, competitively inhibiting kinase activity. It blocks phosphorylation of ROCK substrates such as myosin light chain (MLC) and LIM kinase, suppressing actomyosin contractility and stress fiber formation. Inhibition is dose-dependent, with reported IC₅₀ of ~140 nM for ROCK1 and K_i of 300 nM for ROCK2. Y-27632 shows minimal inhibition of related kinases (PKC, PKA, MLCK, PAK) at concentrations up to 10 μM, confirming high selectivity. Disruption of Rho-mediated cytoskeletal assembly leads to altered cell cycle progression (G1/S transition), impaired cytokinesis, and reduced cell contractility. In stem cells, ROCK inhibition promotes survival by preventing anoikis and apoptosis during dissociation. In cancer models, Y-27632 attenuates invasion and metastasis by impeding actin remodeling required for motility [Zhang et al., 2025].

Evidence & Benchmarks

• Y-27632 inhibits ROCK1 with an IC₅₀ of ~140 nM and ROCK2 with a K_i of 300 nM, demonstrating over 200-fold selectivity against PKC, PKA, MLCK, and PAK (APExBIO, product page).
• In vitro, Y-27632 reduces proliferation of prostatic smooth muscle cells in a concentration-dependent manner (APExBIO, product page).
• In mouse models, Y-27632 administration diminishes tumor invasion and metastasis (APExBIO, product page).
• ROCK inhibition with Y-27632 promotes survival of human stem cells during dissociation and passaging (Zhang et al., 2025, DOI).
• Y-27632 is highly soluble in DMSO (≥111.2 mg/mL), ethanol (≥17.57 mg/mL), and water (≥52.9 mg/mL); solubility is enhanced by warming to 37°C or sonication (APExBIO, product page).
• Long-term storage of stock solutions below -20°C is feasible, but repeated freeze-thaw cycles are not recommended (APExBIO, product page).
• Y-27632 does not significantly inhibit kinases outside the Rho/ROCK family at standard research concentrations (Y-27632.com, URL).

Applications, Limits & Misconceptions

Y-27632 dihydrochloride is a reference tool for dissecting Rho/ROCK signaling in stem cell biology, oncology, and cytoskeletal research. It is used to:

• Enhance viability and cloning efficiency of human pluripotent stem cells and organoids during passaging [Zhang et al., 2025].
• Suppress actin stress fiber formation and modulate cell migration in wound healing and motility assays.
• Reduce tumor invasion and metastatic spread in preclinical cancer models.
• Study cytokinesis, cell cycle checkpoints, and contractility-dependent processes in vitro.

"Y-27632 dihydrochloride: Next-Gen ROCK Inhibitor for Plur..." focuses on advanced stem cell engineering; this article extends those insights by detailing quantitative selectivity, solubility, and protocol parameters required for reproducibility.

"Precision Modulation of Rho/ROCK Signaling: Strategic App..." highlights translational opportunities; we clarify molecular benchmarks and storage/handling nuances.

Common Pitfalls or Misconceptions

• Non-specific kinase inhibition: At recommended concentrations, Y-27632 does not inhibit PKC, PKA, MLCK, or PAK; off-target effects are unlikely unless exceeding 10 μM.
• Permanent cytoskeletal disruption: Y-27632 effects on actin fibers are reversible upon washout; it does not cause irreversible cytoskeletal collapse.
• Universal apoptosis prevention: While Y-27632 prevents dissociation-induced apoptosis in stem cells, it is not a pan-caspase inhibitor and does not block all forms of cell death.
• Direct anti-aging agent: Y-27632 modulates cytoskeletal dynamics but does not directly reverse stem cell aging; its effects on longevity are context-dependent and indirect [Zhang et al., 2025].
• Long-term storage: Aqueous solutions degrade over time; prepare fresh solutions for each experiment when possible.

Workflow Integration & Parameters

Y-27632 dihydrochloride is supplied as a solid by APExBIO (A3008). Stock solutions are typically prepared in DMSO at concentrations up to 10 mM. For optimal solubility, dissolve at room temperature or with gentle warming (37°C) or sonication. Working concentrations in cell culture range from 1–50 μM, depending on cell type and assay. For stem cell passaging, 10 μM is standard. Store solid at 4°C (desiccated); store aliquoted stock solutions at -20°C, minimizing freeze-thaw cycles. Avoid prolonged exposure to air or repeated warming. For in vivo studies, dosing regimens must be validated for each animal model. Monitor for cytotoxicity and off-target effects at higher concentrations. For additional protocol guidance, see the A3008 kit documentation.

Compared to "Y-27632 dihydrochloride: Selective ROCK1/2 Inhibitor for ...", which introduces APExBIO's A3008 kit, this article provides expanded context on in vitro/in vivo integration and troubleshooting.

Conclusion & Outlook

Y-27632 dihydrochloride is a gold-standard, highly selective ROCK1/2 inhibitor for cell and molecular research. Its quantitative selectivity, robust solubility, and reproducible effects on cytoskeletal modulation, cell viability, and tumor invasion make it indispensable for advanced studies in stem cell biology, cancer, and regenerative medicine. APExBIO's A3008 kit exemplifies quality and traceability in research workflows. As Rho/ROCK signaling remains a central node in cell biology, Y-27632 will continue to underpin innovation in basic and translational science. For product specifications and ordering, visit Y-27632 dihydrochloride.